Aluminum (Al) is a neurotoxicant and is implicated in several neurodegenerative diseases, including Alzheimer's disease (AD). In AD brains, one of the pathological hallmarks is the extracellular deposition of senile plaques, which are mainly composed of aggregated amyloid-b (Ab). Endoproteolysis of the amyloid-b precursor protein (AbPP) by the b-secretase and the g-secretase generates Ab. AbPP can also be cleaved by the a-secretase within the Ab region, which releases a soluble fragment sAPPa and precludes the formation of Ab. Al has been reported to increase the level of Ab, promote Ab aggregation, and increase Ab neurotoxicity. In contrast, small G protein Rho and its effector, Rho-associated kinase (ROCK), are known to negatively regulate the amount of Ab. Inhibition of the Rho-ROCK pathway may underlie the ability of nonsteroidal antiinflammatory drugs and statins to reduce Ab production. Whether the Rho-ROCK pathway is involved in Al-induced elevation and aggregation of Ab is unknown. In the present study, cultured rat cortical neurons were treated with Al(malt) 3 in the absence or presence of ROCK inhibitor Y-27632. After the treatment of Al(malt) 3 , the cell viability and the level of sAPPa were reduced, whereas the amyloid fibrils in the conditioned media were increased. Treatment with Y-27632 prevented these adverse effects of Al(malt) 3 and thus maintained neuronal survival. These results reveal that the activation of the Rho-ROCK signaling pathway was involved in Al-induced effects in terms of the cell viability, the production of sAPPa, and the formation of amyloid fibril, which provides a novel mechanism underlying Al-induced neurotoxicity.
Aluminum (Al) is environmentally abundant but not an essential element. Because Al has long been used in industry, medicine, food processing, agriculture, and treatment of water, it may enter the human body from the environment, drinking water, diet, or medication. In the last few decades, the adverse effects of chronic Al exposure have been reported. In particular, Al is confirmed to be a neurotoxicant and is implicated in several neurodegenerative diseases including Alzheimer's disease (AD), the most frequent form of senile dementia (Bharathi et al., 2008; Kawahara, 2005; Shcherbatykh and Carpenter, 2007) . However, the role of Al in the pathogenesis of AD still remains controversial. For example, some studies confirmed elevated levels of Al in AD brains (Bouras et al., 1997; Crapper et al., 1973; Xu et al., 1992) , whereas other studies failed (Bjertness et al., 1996; Landsberg et al., 1992; McDermott et al., 1979) .
In a variety of pathological, neurobehavioral, and epidemiological studies, both neuropathological changes and cognitive impairments similar to those of AD were found following Al exposure, indicating that Al can contribute to the pathogenesis of AD and acts as an environmental risk factor (Kawahara, 2005) . One of the pathological hallmarks in AD brains is the extracellular deposition of senile plaques, which are mainly composed of aggregated amyloid-b (Ab) (Mehta, 2007) . Ab is a small peptide derived from a two-step proteolytic cleavage of a large transmembrane glycoprotein, the amyloid-b precursor protein (AbPP). b-secretase first cleaves the ectodomain of AbPP to generate a membrane-bound fragment, then a subsequent intramembrane cleavage by the c-secretase further generates Ab peptides, mainly of 40 or 42 amino acids in length, termed Ab 1-40 and Ab (Thinakaran and Koo, 2008) . Ab is produced as a monomer but readily aggregates to form dimers, oligomers, protofibrils, and finally fibrils (Glabe, 2004; LaFerla et al., 2007) . AbPP could also be proteolytically processed by a-secretase, which is nonamyloidogenic because the cleavage occurs within the sequence of Ab and generates a secreted form of soluble fragment (sAPPa) that is actually neuroprotective (Thinakaran and Koo, 2008) .
It has been shown that the formation of insoluble Ab fibrils, i.e., the aggregation of Ab peptides and the formation of b-pleated sheet structures, enhances its neurotoxicity and is considered to be responsible for the pathogenesis of AD (Irie et al., 2005; Pike et al., 1991) . Notably, Ab 1-42 , the more abundant Ab species in senile plaques Iwatsubo et al., 1994) , is more directly neurotoxic (Zhang et al. 2002; Zou et al. 2003) and has a greater propensity to aggregate (Arimon et al., 2005; Harper et al., 1997) . In addition to increasing the level of Ab (Campbell et al., 2000) , Al appears to be the most efficient metal cation in promoting Ab aggregation in vitro and in increasing Ab neurotoxicity (Exley et al., 1993; Kawahara et al., 1994 Kawahara et al., , 2001 Kuroda et al., 1995; Ricchelli et al., 2005) . Most importantly, in an animal model, chronic dietary administration of Al can increase Ab levels and accelerate plaque deposition (Pratico et al., 2002) . In AD brains, Al has been found colocalized with Ab 1-42 in senile plaque cores (Yumoto et al., 2009) . These findings support the notion that Al acts as a risk factor for the development of AD through enhancing Ab neurotoxicity.
Various pharmacological agents have been shown to be beneficial in either preventing the onset or delaying the progression of AD. Among them, epidemiological studies revealed that nonsteroidal anti-inflammatory drugs (NSAIDs) reduced the prevalence of AD (Szekely et al., 2004) . A subset of NSAIDs have been reported to preferentially reduce the secretion of Ab 1-42 independent of their inhibitory effects on cyclooxygenase (COX) activity in cultured cells (Weggen et al., 2001) . Further studies found that small G protein Rho and its effector, Rho-associated kinase (ROCK), regulated the amount of Ab 1-42 produced in vitro and that only those NSAIDs effective as Rho inhibitors lowered Ab 1-42 (Zhou et al., 2003) . Although some studies suggested that the decrease in Ab 1-42 production by NSAIDs is because of their direct inhibitory effects on c-secretase rather than because of the inhibition of the Rho-ROCK pathway (Takahashi et al., 2003; Weggen et al., 2003) , the Rho-ROCK pathway has become an attractive target for the development of drugs for treating central nervous system disorders, including AD (Kubo et al., 2008) .
Whether the Rho-ROCK pathway is involved in Al-induced elevation and aggregation of Ab is unknown. Because the hippocampus and cerebral cortex in humans and rodents can accumulate Ab, they are considered AD vulnerable regions (Caccamo et al., 2005) . Therefore, in the present study, cultured rat cortical neurons were treated with Al compound in the absence or presence of ROCK inhibitor, and then, the subsequent changes of cell viability, Ab fibril formation, and AbPP processing were evaluated to confirm the role of Rho activity.
MATERIALS AND METHODS
Chemicals and reagents. Hank's balanced salt solution (HBSS), fetal bovine serum (FBS), Dulbecco's modified Eagle's medium (DMEM), B27 supplement, Glutamax-I, penicillin, and streptomycin were purchased from Gibco (NY). Nupage Bis-Tris gel, SDS sample buffer, MES running buffer, and Nupage transfer buffer were purchased from Invitrogen (CA). Mouse antiAb 1-17 monoclonal antibody (6E10) was purchased from Signet (MA). Rabbit anti-APP polyclonal antibody was purchased from Cell signaling (MA). Antiactin monoclonal antibody and horseradish peroxidase (HRP)-conjugated antibodies were obtained from Chemicon (CA). Y-27632 was obtained from Calbiochem (CA). AlCl 3 Á6H 2 O, maltol, trypan blue, thioflavin, and other reagent-grade chemicals for buffers were purchased from Sigma (MO).
Primary culture of cortical neurons. All experiments were performed according to the guidelines laid down by the Institutional Animal Care and Use Committee of Kaohsiung Medical University. Primary cortical neurons were prepared from neonatal Sprague-Dawley rats as previously established (Chen et al., 2009) . In brief, whole cerebral cortex cut into small pieces was digested with 0.25% trypsin/EDTA in HBSS without calcium or magnesium at 37°C for 15 min. The pieces were then gently rinsed in HBSS, washed twice in plating medium (10% FBS in DMEM), and gently triturated in plating medium through a fire-polished Pasteur pipette. Cell suspension was centrifuged at 43 3 g for 5 min. Pellets were resuspended and then~4-5 3 10 6 cells/ml were plated on poly-D-lysine precoated plastic dishes. Cultures were maintained at 37°C in a 5% CO 2 incubator. After 24 h, the medium was replaced with DMEM containing 2% B27 supplement, 500lM Glutamax, 100 U/ml penicillin, and 100 lg/ml streptomycin. Cytosine arabinoside at 5lM was also added to inhibit the proliferation of nonneuronal cells. The culture medium was changed every 3 days, and the neurons were used for experiments after 6 days in vitro (DIV).
Preparation of stock solutions. Aluminum maltolate (Al(malt) 3 ) is a stable membrane-permeable compound formed by maltol and Al and is known to be a potent neurotoxin (Johnson et al., 2005; Kawahara et al., 2001) . This Al compound is advantageous to in vitro studies because it dose not form insoluble precipitates of Al-hydroxide at physiological pH, as do most other Al compounds (Johnson et al., 2005) . Maltol is a common component in human diet, which can be found in coffee, soybean, baked cereals, and caramelized and browned foods. It has been found that maltol can form a stable complex with Al (Al(malt) 3 ) and enhances Al toxicity (Kawahara, 2005) . Moreover, maltol may facilitate the entry of Al into the brain (van Ginkel et al., 1993) . Oral administration of Al(malt) 3 has been reported to result in increased brain Al (Kaneko et al., 2004) . Therefore, in the present study, Al(malt) 3 was prepared from aluminum chloride hexahydrate (AlCl 3 Á6H 2 O) and maltol (3-hydroxy-2-methyl-4-pyrone) as described previously (Bertholf et al., 1989) . The stock solutions of 25mM Al(malt) 3 , 75mM maltol, and 5mM ROCK inhibitor Y-27632 were dissolved in double-distilled water and sterilized using a 0.2-lm filter.
Pharmacological treatments. Cells at 6 DIV were treated with culture medium containing Al(malt) 3 or maltol at various concentrations as indicated for 1, 3, 5, and 7 days. As for the treatment of ROCK inhibitor, Y-27632 was added into cultures at 6, 8, 10, and 12 DIV and maintained for 7, 5, 3, and 1 days, respectively. When treating cells with Al(malt) 3 in the presence of Y-27632, Al(malt) 3 at 12.5lM was given to cells at 6 DIV and maintained for 7 days, whereas Y-27632 at 25lM was given to cells at 6, 8, 10, and 12 DIV and maintained for 7, 5, 3, and 1 days, respectively.
Cell viability assay. Cell viability was determined by MTT (3-(4,5-dimethylthiaxol-2-yl)-2,5-diphenyl tetrazolium bromide) assay and cell counting after trypan blue staining. Dissociated neurons of rat cerebral cortex were plated on poly-D-lysine-coated 96-well plates for MTT assay and on poly-D-lysine-coated plastic dishes for trypan blue staining. Then, cells at 6 DIV were treated with culture medium containing various reagents for several days as indicated in the previous section of pharmacological treatments. The pH value of the culture medium was not changed after the application of Al(malt) 3 , maltol, or Y-27632. At the end of treatment, the cell viability was assessed. For MTT assay, MTT (5 mg/ml in PBS) with a final concentration of 0.5 mg/ml was added into cultures and incubated for 4 h at 37°C. After removing the MTT-containing culture medium, solubilization buffer (10% SDS in 0.01 N HCl, 200 ll) was added and incubated at 37°C overnight. Finally, the absorbance was measured at 540 nm on a Dynex MRX microplate reader. Cell viability was determined from four wells for each condition and normalized to parallel controls. Each well was treated as a single observation. Data were obtained from three separate experiments with n ¼ 12. For trypan blue staining, cells were stained with trypan blue (0.04%) at 37°C for 5 min and visualized Y-27632 PREVENTS AL-INDUCED NEUROTOXICITY 265 under a light microscope. Cells with damaged membrane (dead cells) were stained blue. Then, trypan blue-positive and nonstained cells were counted separately in 10 randomized fields for each culture dish. The percentage of nonstained cells was determined to reveal the survival rate. Data were obtained from two independent experiments with n ¼ 20.
Thioflavin T fluorescence assay. As aforementioned, the formation of amyloid fibrils is considered an important step in the pathogenesis of AD. To determine the extent of amyloid fibril formation in the conditioned medium, the Thioflavin T (ThT) fluorescence assay was performed. ThT is a benzothiazole dye which undergoes a characteristic spectral alteration upon binding to b-sheet aggregate structures, such as amyloid fibrils. It will bind neither amorphous aggregates nor monomeric Ab and is routinely used to quantify the extent of amyloid fibril formation in solution (House et al., 2004; LeVine, 1993) .
After treating cultured neurons with Al(malt) 3 (12.5lM, 7 days) in the absence or presence of Y-27632 (25lM, 3-7 days), the media were collected and centrifuged (15,000 3 g, 4°C, 5 min) to remove cellular debris. The supernatant was precipitated with 20% trichloroacetic acid at 4°C for 30 min and then spun at 19,000 3 g (4°C) for 90 min. The pellet was resuspended in acetone and spun again for 1 h at 19,000 3 g (4°C). After decanting the acetone, the pellet was resuspended in 100 ll glycine-NaOH. For measuring ThT fluorescence, the assay was carried out according to the protocol previously reported (House et al., 2004) with slight modification. Initially, in the absence of added ThT, the background fluorescence was determined by a fluorescence spectrophotometer over a 5-min period to ensure that a stable fluorescence reading could be taken. Excitation and emission wavelengths were 460 and 495 nm, respectively. ThT in glycine-NaOH was then added to the sample to give a final concentration of 10lM, and the fluorescence reading was determined as before. The final fluorescence was obtained by subtracting the background fluorescence. Five independent experiments were performed.
Analysis of AbPP processing by Western blotting. After pharmacological treatment, 1 ml of culture medium was collected and treated with protease inhibitor cocktail (Roche, Baden-Württemberg, Germany). Proteins were then isolated from culture medium by adding 1 ml of acetone and rocking slowly at 4°C for 1 h, followed by a centrifugation at 19,000 3 g (4°C) for 10 min. The pellet was redissolved in 75 ll double-distilled water and 25 ll 43 sample buffer. For detecting the level of sAPPa, 20 ll of the mixed solution was subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis using 4-12% Bis-Tris gel and blotted onto polyvinylidene difluoride (PVDF) membrane, incubated overnight at 4°C with the mouse anti-Ab 1-17 monoclonal antibody 6E10 (1:500), washed, and incubated with HRP-conjugated goatanti-mouse IgG (1:2000), followed by enhanced chemiluminescence revelation (Perkin Elmer, MA). The protein levels of sAPPa were quantified using densitometric analysis. Three independent experiments were performed and each experiment was repeated in triplicate.
In addition, the cellular levels of AbPP were also evaluated. Cells were washed with PBS after removing the culture medium and then were homogenized in 50mM (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) (PH 7.5), 150mM sodium chloride, 1% deoxycholate, 1% Triton X-100, 0.1% SDS, 1mM ethylene glycol tetraacetic acid, 5mM EDTA, and protease inhibitor cocktail. Thereafter, cell lysate was centrifuged at 16,500 3 g for 20 min at 4°C and the supernatant was quantified for total protein concentration by the BCA assay (Thermo Scientific Pierce, CA). Protein samples (50 lg per sample) were then resolved by 10% Bis-Tris gels and transferred to PVDF membrane. Membranes were incubated with 5% bovine serum albumin blocking buffer for 1 h at room temperature to block the nonspecific binding. Following incubation with the primary antibody against APP (1:1000) or actin (1:5000) overnight at 4°C, the blots were washed in TTBS (0.1% Tween 20, 0.05M Tris in 0.9% NaCl, pH 7.4) and then incubated with the HRP-conjugated goat-anti-rabbit or goat-anti-mouse IgG (1:2000) for 1 h. Blots were then washed five times with TTBS. Immunolabeling was detected using chemiluminescence reagents (Perkin Elmer), and the protein levels were quantified using densitometric analysis. Five independent experiments were performed, and each experiment was repeated in duplicate.
Statistical analysis. Data from cell viability assay (MTT assay and trypan blue staining), ThT fluorescence assay, and densitometric analysis were shown as mean ± SD. Statistical significance was analyzed by one-way ANOVA and post hoc test. The significance level was set at p < 0.05.
RESULTS
Al(malt) 3 reduced cell viability in both time-and dosedependent manners
Cultured cortical neurons (6 DIV) were treated with Al(malt) 3 at various concentrations from 5 to 200lM for 1, 3, 5, and 7 days. The maltol control (600lM) was added to cultures at three times molar concentrations because each molecule of Al binds three molecules of maltol (Johnson et al., 2005; Kawahara et al., 2001) . MTT assay was then performed to examine the changes of cell viability, and the values of nontreated control groups were normalized to 100%. After treating cells with Al(malt) 3 , a significant decrease of cell viability in both time-and dose-dependent manners was observed (Fig. 1A) . In order to provide sufficient time for the formation of Ab aggregation and have a greater potential for the recovery from neurotoxicity, a single treatment of Al(malt) 3 at 12.5lM for 7 days, causing cell viability decreased to around 75% (**p < 0.01, compared with the control group), would be selected for the following experiments. Although the treatment of maltol at 600lM time dependently reduced cell viability (Fig. 1A) , treating cells with maltol at 37.5lM for 7 days had no significant effects on cell viability (p > 0.05, compared with the control group) (Fig. 1B) , which indicates that maltol played no essential role for the neurotoxicity induced by treating cells with Al(malt) 3 at 12.5lM for 7 days.
ROCK inhibitor prevented Al(malt) 3 -induced reduction of cell viability Y-27632 is a well-characterized ROCK inhibitor (Ishizaki et al., 2000) . According to Zhou et al. (2003) , Y-27632 at 25lM was used to inhibit the Rho-ROCK signaling in this study. Cultured cortical neurons at 12, 10, 8, and 6 DIV were treated with Y-27632 for 1, 3, 5, and 7 days, respectively, so that all treated neurons were harvested at 13 DIV. Values obtained from MTT assay with nontreated control group normalized to 100% showed no significant changes in cell viability after treating cells with Y-27632 for 1-7 days (p > 0.05, compared with the control group) (Fig. 2A) . Similarly, survival rates obtained from trypan blue staining also showed no significant changes after treating cells with Y-27632 for 1-7 days (p > 0.05, compared with the control group). All survival rates were around 95% (Fig. 2B) .
Subsequently, cultured cortical neurons at 6 DIV were treated with Al(malt) 3 at 12.5lM for 7 days, and Y-27632 at 25lM was added to these cultures at 6, 8, 10, and 12 DIV for 7, 5, 3, and 1 days, respectively. The results of MTT assay showed that Al(malt) 3 alone significantly reduced the cell viability to around 78% (**p < 0.01, compared with the control group) (Fig. 2C) . While treating cells with Al(malt) 3 in the presence of Y-27632 for 1 day, the cell viability was still significantly reduced (around 87%, *p < 0.05, compared with the control group) (Fig. 2C) . However, after treating cells with Al(malt) 3 in the presence of Y-27632 for 3, 5, and 7 days, the cell viabilities were increased to > 90%, which were not significantly different from that of the control group (p > 0.05) but were significantly higher than that of the Al(malt) 3 -treated group ( # p < 0.05, ## p < 0.01) (Fig. 2C) . As for the results of trypan blue staining, the survival rate of the control group was 95.1 ± 5%. Al(malt) 3 alone significantly reduced the survival rate to 83.8 ± 5% (**p < 0.01, compared with the control group) (Fig. 2D ). Treating cells with Al(malt) 3 in the presence of Y-27632 for 1, 3, and 5 days, the survival rates were still significantly lower than that of the control group (89.7 ± 4%, 89.9 ± 6%, and 87.7 ± 5%, respectively, *p < 0.05, compared with the control group) (Fig. 2D) . When compared with the Al(malt) 3 -treated group, the survival rates for cells treated with Al(malt) 3 in the presence of Y-27632 for 1, 3, and 7 (92.5 ± 3%) days were significantly increased (#p < 0.05, compared with the Al(malt) 3 -treated group). These results indicate that Y-27632 could prevent Al(malt) 3 -induced reduction of cell viability.
ROCK inhibitor prevented Al(malt) 3 -induced increase of amyloid fibril in the conditioned medium
The extent of amyloid fibril formation in the conditioned medium was evaluated by the ThT fluorescence assay in which the fluorescence emission by ThT was measured. After treating cells with Al(malt) 3 at 12.5lM for 7 days, the ThT fluorescence was significantly increased (~1.3 3 fluorescence intensity of the nontreated control group) (*p < 0.05, compared with the control group) (Fig. 3) . In contrast, while treating cells with Al(malt) 3 in the presence of Y-27632 for 3, 5, and 7 days, the ThT fluorescence did not change significantly (p > 0.05, compared with the control group) (Fig. 3) . In particular, the treatments of Y-27632 for 5 and 7 days significantly reduced Al(malt) 3 -induced increase of ThT fluorescence ( # p < 0.05 and ## p < 0.01, respectively, compared with the Al(malt) 3 -treated group). These results indicate that the treatment of Al(malt) 3 induced a significant formation of amyloid fibril, and the presence of ROCK inhibitor prevented this effect.
ROCK inhibitor prevented Al(malt) 3 -induced decrease of sAPPa
Because the secretion of sAPPa precludes the production of amyloidogenic Ab, the levels of sAPPa in the media were measured by Western blotting analysis. In Fig. 4 , densitometric data were shown as mean ± SD with the nontreated control group normalized to 1.0. After treating cells with Al(malt) 3 at 12.5lM for 7 days, the level of sAPPa in the medium was significantly decreased (0.67 ± 0.29, *p < 0.05, compared with the control group). In contrast, while treating cells with Al(malt) 3 in the presence of Y-27632 for 3, 5, and 7 days, the levels of sAPPa were not significantly different from that of the control group (1.02 ± 0.21, 0.99 ± 0.26, and 1.08 ± 0.24, respectively, p > 0.05) but were significantly higher than that of the Al(malt) 3 -treated group ( # p < 0.05) (Fig. 4A ). In addition, full-length AbPP levels were also analyzed by Western blotting. No significant change in cellular levels of AbPP was found after the treatments of Al(malt) 3 in the absence or presence of Y-27632 (p > 0.05, compared with the control group) (Fig. 4B) . These results indicate that Al(malt) 3 -induced decrease of sAPPa was not because of a reduction in the level of AbPP following the treatment of Al(malt) 3 .
DISCUSSION
Epidemiological studies have revealed an association between chronic exposure to Al in drinking water and risk of AD (Flaten, 2001; Gauthier et al., 2000; Martyn et al., 1989) .
FIG. 1.
Cell viability of cultured cortical neurons was significantly decreased after treatment with Al(malt) 3 (A) and was relatively much less sensitive to maltol (B). Values obtained from MTT assay were normalized to nontreated control values and shown as mean ± SD. Statistical significance was analyzed by one-way ANOVA and post hoc test (Tukey test). *p < 0.05; **p < 0.01 indicate significant differences relative to respective control.
Y-27632 PREVENTS AL-INDUCED NEUROTOXICITY
Although Al can reach and accumulate in almost every organ in the human body, the central nervous system is a particular target of the deleterious effects. Various mechanisms have been proposed to underlie Al-induced neurotoxicity, including oxidative stress (Bhalla and Dhawan, 2009; Kaneko et al., 2004) , effects on cell signaling (Fu et al., 2003; Johnson et al., 2005; Nostrandt et al., 1996) , disruption of calcium homeostasis (Konoha et al., 2003) , perturbation of mitochondrial functions (Dewitt et al., 2006; Kumar et al., 2008) , and alteration of phosphorylation level of neurofilaments (Kaur et al., 2006; Kushkuley et al., 2010) . However, the contribution of Al to AD still needs further investigations. During the development of AD, extracellular accumulation of Ab in the brain is regarded as an early event when a massive cell death is not seen (Mucke et al., 2000) . Notably, Al has been found to enhance the production and aggregation of Ab both in in vitro and in in vivo studies (Campbell et al., 2000; Kawahara et al., 2001; Ricchelli et al., 2005) ; however, its underlying mechanism is uncertain.
In the present study, cultured rat cortical neurons were treated with Al(malt) 3 at 12.5lM for 7 days in the absence or presence of ROCK inhibitor Y-27632 at 25lM for 3-7 days. After the treatment of Al(malt) 3 alone, the cell viability and the level of sAPPa were reduced, whereas the ThT fluorescence in the conditioned media was increased. In contrast, the treatment of ROCK inhibitor Y-27632 prevented these adverse effects of Al(malt) 3 and thus maintained neuronal survival. These results indicate that the activation of the Rho-ROCK signaling pathway was involved in Al-induced neurotoxicity through interfering with the AbPP processing and the formation of amyloid fibrils, which provides a novel mechanism underlying Al-induced neurotoxicity.
FIG. 2.
ROCK inhibitor, Y-27632, alone had no significant effect on cell viability of cultured cortical neurons (A and B) but could prevent Al(malt) 3 -induced reduction of cell viability (C and D). Values obtained from MTT assay were normalized to nontreated control values, and those obtained from trypan blue staining were shown as survival rates. All data were shown as mean ± SD. Statistical significance was analyzed by one-way ANOVA and post hoc test (Tukey test). *p < 0.05; **p < 0.01 indicate significant differences relative to control, and #p < 0.05; ##p < 0.01 indicate significant differences relative to group of Al(malt) 3 treatment alone. Among many Al compounds, lipophilic Al(malt) 3 formed by maltol and Al was used as an optimal neurotoxicant in the present study. Maltol, widely used as a flavor-enhancing agent and present in baked products as well as Korean ginseng root, can exert a neuroprotective effect through its antioxidant action (Kang et al., 2006; Kim et al., 2004) . However, maltol is also reported to be toxic to both human and murine neuroblastoma cell lines and to primary murine fetal hippocampal neurons in a dose-dependent manner at micromolar concentrations (Hironishi et al., 1996) . In addition, maltol has been demonstrated to enhance Al toxicity in neuronal cells (Langui et al., 1990; Savory et al., 1993) . In the present study, the treatment of maltol reduced cell viability in both time-and dose-dependent manners (Fig. 1) . However, the treatment of maltol at 37.5lM for 7 days did not change the cell viability significantly (Fig. 1B) , indicating that treating cells with Al(malt) 3 at 12.5lM for 7 days is an appropriate condition for the following evaluations of Al-induced effects.
As mentioned previously, an overabundance of Ab has been found in the center core of senile plaques Iwatsubo et al., 1994) . Al can form a complex with Ab, which further reduces the solubility of Ab through increasing the precipitation of b-sheet aggregate (Kawahara et al., 1994 (Kawahara et al., , 2001 Ricchelli et al., 2005) . Previous studies have demonstrated that Ab peptides containing b-sheet structure are directly incorporated into neuronal membranes, forming Ca 2þ -permeable ion channels and causing elevation of intracellular Ca 2þ levels and finally death of neurons (Arispe et al., 1993; Furukawa et al., 1994; Kawahara, 2004; Kawahara et al., 2009 ). According to these findings, Al can facilitate the formation of Ab amyloid fibrils and thus leads to the disruption of calcium homeostasis, which plays an important role in Al-induced neurotoxicity. However, the mechanisms underlying the enhanced formation of amyloid fibril following Al exposure are still uncertain.
The Rho GTPase family, including Rho, Rac, and Cdc42, are key regulators of actin dynamics, leading to organized actin-based structures associated with the structure and motility of cells. In the nervous system, numerous extracellular stimulants and inhibitors of motility and neurite outgrowth appear to signal through the Rho GTPases (Meyer and Feldman, 2002) . Among the Rho GTPase family, Guanosine-5#-triphosphate-bound form of Rho can activate ROCK, a serine/threonine protein kinase (Matsui et al., 1996) . This Rho-ROCK pathway is involved in many neuronal functions, including neurite outgrowth and retraction (Hirose et al., 1998; Jalink et al., 1994) . Because inhibitors of neurite outgrowth usually activate Rho (Meyer and Feldman, 2002) , the inhibition of the Rho-ROCK pathway promotes axonal regeneration and functional recovery in the damaged central nervous system (Kubo et al., 2008) . Furthermore, the Rho-ROCK pathway has been reported to negatively modulate AbPP processing by a-secretases. As aforementioned, NSAIDs have been shown to stimulate the secretion of the nonamyloidogenic sAPPa (Avramovich et al., 2002) and lower Ab 1-42 levels by inhibiting the activity of Rho through the perturbation of its isoprenylation (Zhou et al., 2003) . In addition to NSAIDs, statins (HMG-CoA reductase inhibitors) also have apparent ability to decrease the risk for AD. In cultured neuroblastoma cells transfected with human Swedish mutant APP, statins activated a-secretase cleavage and thus stimulated the release of sAPPa via the inhibition of the Rho-ROCK pathway, which precluded the formation of toxic FIG. 4 . The level of sAPPa decreased significantly after the treatment of Al(malt) 3 , which could be prevented by ROCK inhibitor, Y-27632 (A), whereas the cellular levels of AbPP showed no significant change after the treatments of Al(malt) 3 in the absence or presence of Y-27632 (B). Values obtained from Western blotting analysis were normalized to nontreated control values and shown as mean ± SD. Statistical significance was analyzed by one-way ANOVA and post hoc test (LSD test). *p < 0.05 indicates significant difference relative to control, and #p < 0.05 indicates significant differences relative to group of Al(malt) 3 treatment alone.
Y-27632 PREVENTS AL-INDUCED NEUROTOXICITY amyloid aggregates (Pedrini et al., 2005) . In primary cortical neurons, statin-regulated sAPPa secretion occurs partly through inhibiting the Rho-ROCK pathway (Ma et al., 2009) . Although, until now, neither APP nor a-secretases are known as direct targets of ROCK's kinase activity, the inhibition of Rho and ROCK activity underlies the ability of NSAIDs and statins to reduce Ab production and aggregation.
In our results, ThT fluorescence was significantly increased after treating cells with Al(malt) 3 (Fig. 3) , which indicates that Al(malt) 3 enhanced the formation of amyloid fibrils. In the presence of Y-27632, Al(malt) 3 -induced increase of ThT fluorescence was prevented, indicating that the activation of the Rho-ROCK pathway may contribute to the enhanced b-sheet aggregates formation following Al(malt) 3 treatments (Fig. 3) . In addition, Al(malt) 3 alone decreased the secretion of sAPPa but did not change the cellular level of AbPP (Fig. 4) . Because the release of sAPPa from AbPP that is proteolytically processed by a-secretase precludes the formation of Ab, this finding indirectly supports that Al(malt) 3 may facilitate Ab production. In the presence of Y-27632, Al(malt) 3 -induced reduction in the secretion of sAPPa was prevented (Fig. 4) , indicating that the activation of the Rho-ROCK signaling may contribute to the enhanced Ab production following Al(malt) 3 treatments.
In summary, Al(malt) 3 can exert its effects through activating the Rho-ROCK pathway. The inhibition of the Rho-ROCK pathway not only maintained the cell viability but also prevented both Al(malt) 3 -induced increase in the formation of amyloid fibril and Al(malt) 3 -induced reduction in the level of sAPPa. These results provide the first evidence for the involvement of the Rho-ROCK signaling pathway in Al-induced neurotoxicity. 
